TG Therapeutics, Inc.
TGTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United. With a market capitalization of $8.40B, it sits in mid-cap territory. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Market Cap
$8.40B
Beta
1.60
P/E (TTM)
19.25
P/E (Fwd)
16.72
EPS (TTM)
$2.85
EPS (Fwd)
$3.28
ROE
112.6%
ROA
8.6%
Cash
$514.4M
Total Debt
$753.6M
Free CF
-$30.2M
52W Change
44.7%
Annual Financials
Cash vs Debt
TG Therapeutics, Inc. carries $753.6M in total debt against $514.4M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$30.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 112.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.8M (2022) to $616.3M (2025), reflecting a 22029% increase over the period.
With a beta above 1.5, TGTX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TG Therapeutics, Inc. and its sector.